Subcutaneous Immunotherapy Scit Articles & Analysis
3 news found
Any patient who would be adversely impacted by a discontinuation period in their subcutaneous immunotherapy (SCIT aka allergy shots) is eligible. About Oral Mucosal Immunotherapy (OMIT) Respiratory allergies affect at least 60 million people in the United States, resulting in 11.1 million visits to the doctor in 2010. 100 ...
Allovate Therapeutics (“Allovate®”), a New York-based biotechnology company focused on improving treatment for allergies, is pleased to announce the appointment of Robert "Bob" Pomrenke to the position of Chief Executive Officer, effective April 1, 2019. Mr. Pomrenke brings over 25 years of sales, marketing and business development experience in the allergy immunotherapy market. ...
Allovate Therapeutics, a biopharmaceutical company focused on improving treatment for allergies, announced today that the U.S Patent and Trademark Office (USPTO) has granted U.S. Patent No. 9,271,899 entitled, “Methods, Articles and Kits for Allergic Desensitization, via the Oral Mucosa.” The issuing patent including claims to the approach of combining allergenic proteins with ...